APA (7th ed.) Citation

Burmester, G. R., Stigler, J., Rubbert-Roth, A., Tanaka, Y., Azevedo, V. F., Coombs, D., . . . Gensler, L. S. (2024). Safety Profile of Upadacitinib up to 5 Years in Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis: An Integrated Analysis of Clinical Trials. Rheumatology & Therapy, 11(3), 737. https://doi.org/10.1007/s40744-024-00671-4

Chicago Style (17th ed.) Citation

Burmester, Gerd R., et al. "Safety Profile of Upadacitinib Up to 5 Years in Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis: An Integrated Analysis of Clinical Trials." Rheumatology & Therapy 11, no. 3 (2024): 737. https://doi.org/10.1007/s40744-024-00671-4.

MLA (9th ed.) Citation

Burmester, Gerd R., et al. "Safety Profile of Upadacitinib Up to 5 Years in Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis: An Integrated Analysis of Clinical Trials." Rheumatology & Therapy, vol. 11, no. 3, 2024, p. 737, https://doi.org/10.1007/s40744-024-00671-4.